news
Zotiraciclib granted Orphan Drug Designation by FDA and EMA
The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.
List view / Grid view
Chemotherapy
Filter the results
news
Precise cancer treatment possible with new nanotube drug delivery technology
A new drug delivery technology has been developed using nanotubes which can efficiently and precisely target lung cancer cells.
news
Targeted radiation using TARE-Y90 for children with liver cancer
A review of a study on children with liver cancer has shown the effectiveness of Transarterial Radioembolization with Yttrium-90 as a course of treatment...
Whitepapers/App Notes/Posters
Application Note: Gas safety in the laboratory
Modern laboratories use a number of gases as part of their daily operations. This application note details two of the most common methods of laboratory gas supply, and their associated safety risks and benefits...
news
Cardiac monitoring for high-risk breast cancer patients ‘should be prioritised’
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
news
Senescent cells targeted with new nanocarrier drug delivery system
Senescent, or zombie cells, are being targeted with the development of a new nanocarrier drug delivery system.
news
Talazoparib shows promise for early-stage BRCA+ breast cancer patients
Once-daily oral pill could replace preoperative chemotherapy in patient population if validated in larger trials...
news
AIBP injection alleviates chemotherapy pain for months in mice
Protein inhibits inflammatory response underlying chronic pain processing may provide an alternative to opioids for severe, persistent pain...
news
Improved method of delivering anti-cancer drugs
A new non-toxic method for delivering anti-cancer drugs to specific parts of the human body could mean the end of the severe side effects...
news
Antibiotics may impact cancer treatment efficacy
Improper use of antibiotics may have an unintended consequence of hampering cancer treatments...
article
Meeting access challenges with adaptive trial designs
With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…
news
Shorter treatment course better for intermediate risk prostate cancer?
New research suggests that treatment with a shorter course of radiation using higher doses over fewer days may be the preferred approach for some men with intermediate-risk prostate cancer.
news
Fat cells may inactivate chemotherapeutic drug
A study has shown that Adipocytes can absorb and metabolise the chemotherapeutic agent daunorubicin, reducing its ability to kill cancer cells.
news
UK trails behind EU in cancer diagnosis & treatment
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
news
Novartis combination targeted therapy receives FDA approval
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.